A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Participants will receive intravenous (IV) glofitamab for up to 3 cycles.

Participants will receive IV obinutuzumab on Cycle 1 Day 1.

Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.

Participants will receive up to 2 doses of IV rituximab.

Participants will receive IV ifosfamide for up to 3 cycles.

Participants will receive IV carboplatin for up to 3 cycles.

Participants will receive IV etoposide for up to 3 cycles.